Management Team


Øystein Soug , Chief Executive Officer

20 years in international banking and industry, the last six of which as CFO of Algeta ASA and was the former CFO of Targovax ASA.

Øystein Soug is the former CFO of Algeta, a Norwegian oncology biotech company which was sold to Bayer for USD 2.9 billion in 2014. Prior to joining Algeta in 2008 Mr. Soug worked for six years at Orkla, lastly as CFO of Orkla’s Russian division.

Mr. Soug started his career as a banker with Credit Suisse and with the European Bank for Reconstruction and Development. Mr. Soug received an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997.


Jon Amund Eriksen , Chief Technology Innovation Officer

Co-founder and inventor of Targovax technology.

More than 30 years of experience in the pharmaceutical and biotech industry in pharma and biotech industry (Nycomed, Norsk Hydro, GemVax, Pharmexa, Lytix Biopharma). Managing positions within development of  cancer immunotherapy from early preclinical to Phase III clinical development.

Co-inventor of several patents for peptide cancer vaccines. MSc chemistry.


Magnus Jaderberg , Chief Medical Officer

A pharmaceutical physician with 25+ years in various R&D functions including clinical research, medical affairs, pharmacovigilance, strategic product development, health economics and general management.

Experienced in all phases of clinical research including clinical pharmacology, dose finding, registration, post-launch product differentiation and surveillance. His immunotherapy expertise includes several compounds including Yervoy (ipilimumab). Prior to joining Oncos, Magnus held roles at national, European and global level at GSK, Pharmacia, Wyeth and most recently as Chief Medical Officer, Bristol Myers Squibb (Europe).

Qualified in medicine at Karolinska Institute, Stockholm, Sweden, and is a fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom, and honorary lecturer in drug development at King’s College.


Tina Madsen , Vice President, Quality Assurance

More than 20 years of experience within Research & Development and commercial manufacturing in the pharmaceutical and biotech industry, including quality assurance, process development and formulation.

Before joining Targovax, she was Director of Product Quality Assurance in Algeta ASA (now Bayer AS).


Anne Kirsti Aksnes , Vice President, Clinical Development

More than 20 years of experience within clinical research and development in the pharmaceutical and biotech industry and 10 years of experience working in clinical physiology.

Previously, she was VP Clinical Research in Algeta ASA (now Bayer AS), where she had a key role in the strategic, scientific and clinical development as well as in medical communications.


Berit Iversen , Vice President, Head of CMC

More than 25 years of experience within Research & Development in the pharmaceutical and biotech industry.

Managing positions within CMC, Analysis, Method development, Quality Assurance and Quality Control. Global cross functional development experience in pharma from preclinical through to regulatory approval. MSc Chemistry, UiO.


Peter Skorpil , Vice President, Business Development

Extensive experience in licensing, commercial assessments, business intelligence and partnering.

Previously, he was Commercial Director in Pronova BioPharma and Business Development Manager for Clavis Pharma where he was responsible for, among other things, out-licensing and managing Clavis partners. Peter has also worked as a venture capital analyst at NeoMed Management.

Peter has a MBA from Brandeis University, Massachusetts, USA and a PhD in molecular biology from University of Geneva, Switzerland.


Erik Digman Wiklund , Chief Financial Officer

Former consultant in the Pharma & Healthcare practice of McKinsey & Company, combined with a PhD in cancer research.

Erik brings experience from management consulting, as well as commercial and operational roles in the biotechnology industry. Most recently he held the position as Director of Product Innovation in the nutraceutical company Aker Biomarine Antarctic AS, and also has experience from the Norwegian oncology success Algeta ASA.

Erik holds a PhD in Molecular Biology from Aarhus University, Denmark, and the Garvan Institute in Sydney, Australia.